Direkt zum Inhalt
Merck
  • Bone marrow stromal cells enhance the osteogenic properties of hydroxyapatite scaffolds by modulating the foreign body reaction.

Bone marrow stromal cells enhance the osteogenic properties of hydroxyapatite scaffolds by modulating the foreign body reaction.

Journal of tissue engineering and regenerative medicine (2012-07-12)
Gregory Tour, Mikael Wendel, Ion Tcacencu
ZUSAMMENFASSUNG

We aimed to investigate the osteogenic properties of bone marrow stromal cell (BMSC)-loaded biomimetic constructs composed of hydroxyapatite (HA), with or without in vitro cell-derived extracellular matrix (HA-ECM), and to assess the cellular components of the elicited foreign body reaction. HA-ECM constructs were produced by adult rat dermal fibroblasts cultured on top of synthetic HA microparticles. Rat calvarial critical-sized defects (8 mm) were created and treated with the generated HA-ECM constructs or HA microparticles, alone or combined with green fluorescent protein (GFP)-expressing BMSCs. The new bone formation and the local cellular inflammatory response (macrophages, neutrophils, lymphocytes, eosinophils and PCNA-index) were assessed by histomorphometry and immunohistochemistry at 2 and 12 weeks postoperatively. In addition, the BMSCs' survival and engraftment were checked. The largest volume of the newly formed bone was found in defects treated with HA-ECM constructs combined with BMSCs (p < 0.05). Moreover, the implanted BMSCs modulated the local inflammatory response, demonstrated by either a significant increase (HA vs HA + BMSCs) or decrease (HA-ECM vs HA-ECM + BMSCs) of the inflammatory cell number. No donor BMSCs were detected at the site of implantation or in the host bone marrow at 2 or 12 weeks postoperatively. In conclusion, the treatment of critical-sized calvarial defects with the BMSC-loaded biomimetic constructs has significantly enhanced bone repair by modulating the foreign body reaction. Our findings highlight the implications of BMSCs in the regulation of the foreign body reaction triggered by tissue-engineered constructs, proving a higher efficiency for the BMSC combination therapy.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ammoniumhydroxid -Lösung, ACS reagent, 28.0-30.0% NH3 basis
Sigma-Aldrich
Ammoniumhydroxid -Lösung, 28% NH3 in H2O, ≥99.99% trace metals basis
Sigma-Aldrich
L-Ascorbinsäure, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-Ascorbinsäure, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L-Ascorbinsäure, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L-Ascorbinsäure, 99%
Sigma-Aldrich
L-Ascorbinsäure, reagent grade, crystalline
Supelco
Ascorbinsäure, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Ascorbinsäure, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
L-Ascorbinsäure, ACS reagent, ≥99%
Supelco
L-Ascorbinsäure, analytical standard
Sigma-Aldrich
L-Ascorbinsäure, meets USP testing specifications
Sigma-Aldrich
Ammoniumhydroxid -Lösung, BioUltra, ~1 M NH3 in H2O (T)
Sigma-Aldrich
L-Ascorbinsäure, reagent grade
Sigma-Aldrich
L-Ascorbinsäure, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L-Ascorbinsäure, FCC, FG
Sigma-Aldrich
L-Ascorbinsäure, BioUltra, ≥99.5% (RT)
Ascorbinsäure, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-Ascorbinsäure, puriss. p.a., ≥99.0% (RT)
Supelco
L-Ascorbinsäure, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Ascorbinsäure, tested according to Ph. Eur.